[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-alzheimers-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-alzheimers-disease":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100471336","low-intensity-focused-ultrasound-for-mild-cognitive-impairment-and-mild-alzheimers-disease-100471336",false,"NCT05417555","Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease","Modulation of Hippocampal Circuitry and Memory Function With Focused Ultrasound in Amnestic MCI","LIFUP-MCIAD","Inclusion Criteria\n\n* Amnestic MCI or Mild Alzheimer's diagnosis\n* Age 50-90\n* English-speaking\n* Ability to provide informed consent\n* Normal or corrected-to-normal hearing and vision\n\nExclusion Criteria\n\nGENERAL\n\n* Participation in another clinical trial\n* Active use of immunotherapeutic medications for cognition (Aduhelm, Leqembi, Kisunla)\n* Moderate to Severe Alzheimer's\n* Inability to provide informed consent\n\nMRI-Related:\n\n* Weight exceeding 275 pounds\n* Pregnancy, suspicion of pregnancy, or attempting to become pregnant\n* Claustrophobia\n* Difficulties during previous MRIs\n* Top permanent retainer (bottom only is okay), 5 or more non-removable gold-teeth, metal braces, top spacers, and\u002For palate expanders\n* Any of the following implants: Cardiac Pacemaker, Aneurysm clips, Cochlear implants, Defibrillator, Electrodes or wires, Magnetically-activated device, Spinal cord stimulator, Infusion or insulin pumps, Implanted drug infusion device, Deep brain stimulation device\n* Non-removable hairpieces, hairpiece extensions, and\u002For piercings\n* Facial tattoos or permanent makeup\n* Metal implants that are MR-incompatible, or where participant is unable to provide sufficient information to determine MR compatibility\n* Previous injury by metallic foreign body (e.g., bullet, BB, shrapnel) where the object entered the body and participant lacks doctor's confirmation that it was fully removed\n\nMedical:\n\n* Diagnosis of one or more of the following neurological disorders: Parkinson's disease, Lou Gehrig's disease (ALS), Multiple sclerosis, Cerebral Palsy\n* Diagnosis of one or more of the following genetic disorders: Cystic Fibrosis, Sickle Cell Disease\n* Diagnosis of one or more of the following psychiatric disorders: Bipolar, Psychosis\n* Psychiatric illness that has not been controlled for at least two months (if controlled \\>2 months, with or without medication, they are not exclusionary)\n* Severe lung, liver, heart, and\u002For kidney disease\u002Fs (e.g., heart failure, liver failure, and etc...)\n* Diagnosis of thyroid disorder or change of thyroid medication dose within the last 3 months\n* Cancer treatment\u002Fs with chemotherapy and\u002For radiation to head and neck, or stage 4 (metastatic) cancer\n* Autoimmune disorder or viral infection such as HIV, COVID 19, or hepatitis C that has caused current problems with cognition\u002Fmemory\n* History of substance abuse in the past year\n* History of stroke (Transient ischemic attack \u002F mini-stroke not exclusionary if symptoms lasted \\\u003C1 week)\n* History of 2 or more seizures or diagnosis of epilepsy, unless the seizures occurred prior to age 5 alongside a fever.\n* History of brain tumor, brain aneurysm, brain hemorrhage, or subdural hematoma (transient ischemic attack not exclusionary)\n* Head injury that resulted in loss of consciousness lasting \\>30 minutes, cognitive issues lasting \\>18 months, and\u002For brain abnormalities visible in CT or MRI scan\n* Uncontrolled high blood pressure or diabetes\n* Heart attack within the last year","ALL","50 Years","90 Years",{"count":21,"type":22},144,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild Cognitive Impairment and Mild Alzheimer's Disease.\n\nThe main questions the study seeks to answer are:\n\n1. Can LIFUP increase brain activity in the targeted area?\n2. Can LIFUP improve memory in people with MCI and mild AD?\n3. Can LIFUP improve connectivity of memory networks in the brain?\n\nParticipants in this study will complete MRIs and memory testing, and receive Low Intensity Focused Ultrasound to a part of their brain involved in memory (the entorhinal cortex).",[28,29,30,31],"Mild Cognitive Impairment","Amnestic Mild Cognitive Disorder","Deep Brain Stimulation","Mild Alzheimer's Disease",[33,34,35,36,37,38,39,40,41,42,43],"deep brain stimulation (DBS)","transcranial focused ultrasound stimulation (tFUS)","memory","low-intensity focused ultrasound pulsation (LIFUP)","fMRI","mild cognitive impairment","mci","noninvasive brain stimulation (NIBS)","ultrasound","Alzheimer's Disease","Mild Alzheimer's","RECRUITING","2026-04-13",{"date":47,"type":48},"2026-04-16","ACTUAL",{"date":50,"type":48},"2022-09-01",{"date":52,"type":22},"2026-07-31",{"name":54,"class":55},"University of California, Los Angeles","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":56},"100520566","medicare-anti-a-mab-coverage-with-evidence-development-ced-study-100520566","NCT06058234","Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study","Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)","Inclusion Criteria:\n\n* Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.\n\nExclusion Criteria:\n\n* none",{"count":65,"type":22},8680,"OBSERVATIONAL","The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).",[31,69],"Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease","2023-09-21",{"date":72,"type":48},"2023-09-28",{"date":74,"type":48},"2023-07-06",{"date":76,"type":22},"2029-06-30",{"name":78,"class":79},"Centers for Medicare and Medicaid Services\u002F Coverage and Analysis Group","FED"]